The authors reply

New England Journal of Medicine

Volumn 365, Issue 3, 2011, Pages 279-

  Borissoff, Julian Ilcheff ^a   Spronk, Henri M H ^a   Ten Cate, Hugo ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; GELATINASE B; MACROPHAGE ELASTASE; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; STROMELYSIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; UROKINASE;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD GROUP SYSTEM; CARDIOVASCULAR DISEASE; COLLAGEN DEGRADATION; DISEASE COURSE; ELASTOLYSIS; EXTRACELLULAR MATRIX; FIBRINOLYSIS; LETTER; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION;

EID: 79960568128     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Bouma BN, Meijers JC. New insights into factors affecting clot stability: a role for thrombin activatable fibrinolysis inhibitor (TAFI; plasma procarboxypeptidase B, plasma procarboxypeptidase U, procarboxypeptidase R). Semin Hematol 2004;41: Suppl 1:13-9. (Pubitemid 38182710)
2. Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T. The impact of the fibrinolytic system on the risk of venous and arterial thrombosis. Semin Thromb Hemost 2009;35:468-77.
3. Lijnen HR. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 2001;86:324-33. (Pubitemid 32663963)
4. Carmeliet P, Moons L, Lijnen R, et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 1997;17:439-44. (Pubitemid 27518393)
5. Luttun A, Lupu F, Storkebaum E, et al. Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2002;22:499-505. (Pubitemid 34218761)